ByteDance spin-off Anew Labs raises US$290m amid AI drug design fundraising boom
- Posted on September 18, 2026
- By South China Morning Post
- 1 Views
- 1 min read
In brief
Anew Labs, a ByteDance subsidiary, secures $290 million in funding as artificial intelligence transforms pharmaceutical development. This investment reflects the accelerating momentum in AI-powered drug discovery, with Chinese biotech companies intensifying capital acquisition strategies. The funding surge underscores growing investor confidence in machine learning applications for accelerating clinical research timelines and reducing development costs in the competitive global pharmaceutical sector.
Summary auto-generated by AI from the original publisher's content. Editorial standards.
ByteDance spin-off Anew Labs raises US$290m amid AI drug design fundraising boom
As AI’s role in drug design advances rapidly, Chinese start-ups are ramping up fundraising efforts.
